<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Reprod Infertil</journal-id><journal-id journal-id-type="iso-abbrev">J Reprod Infertil</journal-id><journal-id journal-id-type="publisher-id">JRI</journal-id><journal-id journal-id-type="pmc">JRI</journal-id><journal-title-group><journal-title>Journal of Reproduction &#x00026; Infertility</journal-title></journal-title-group><issn pub-type="ppub">2228-5482</issn><issn pub-type="epub">2251-676X</issn><publisher><publisher-name>Avicenna Research Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27110520</article-id><article-id pub-id-type="pmc">4819211</article-id><article-id pub-id-type="publisher-id">jri-16-212</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effect of Omega-3 Supplementation on Visfatin, Adiponectin, and Anthropometric Indices in Women with Polycystic Ovarian Syndrome</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nadjarzadeh</surname><given-names>Azadeh</given-names></name><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref><xref ref-type="aff" rid="AFF2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dehghani-Firouzabadi</surname><given-names>Razieh</given-names></name><xref ref-type="aff" rid="AFF3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Daneshbodi</surname><given-names>Hoorieh</given-names></name><xref ref-type="aff" rid="AFF4"><sup>4</sup></xref><xref ref-type="corresp" rid="C1"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lotfi</surname><given-names>Mohammad Hassan</given-names></name><xref ref-type="aff" rid="AFF5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vaziri</surname><given-names>Niloofar</given-names></name><xref ref-type="aff" rid="AFF4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mozaffari-Khosravi</surname><given-names>Hassan</given-names></name><xref ref-type="aff" rid="AFF2"><sup>2</sup></xref></contrib><aff id="AFF1"><label>1-</label>Nutrition and Food Security Research Centre, Shahid Sadoughi University of Medical Sciences, Yazd, Iran</aff><aff id="AFF2"><label>2-</label>Department of Nutrition, Faculty of Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran</aff><aff id="AFF3"><label>3-</label>Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran</aff><aff id="AFF4"><label>4-</label>International Campus, Shahid Sadoughi University of Medical Sciences, Yazd, Iran</aff><aff id="AFF5"><label>5-</label>Department of Biostatistics &#x00026; Epidemiology, Faculty of health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran</aff></contrib-group><author-notes><corresp id="C1"><label>*</label><italic>Corresponding Author</italic>: Hoorieh Daneshbodi, International Campus of Shahid Sadoughi University of Medical Sciences, Yazd, Iran, <italic>E-mail</italic>: <email>h_daneshbodi@ssu.ac.ir</email></corresp></author-notes><pub-date pub-type="ppub"><season>Oct-Dec</season><year>2015</year></pub-date><volume>16</volume><issue>4</issue><fpage>212</fpage><lpage>220</lpage><history><date date-type="received"><day>26</day><month>11</month><year>2014</year></date><date date-type="accepted"><day>03</day><month>3</month><year>2015</year></date></history><permissions><copyright-statement>Copyright&#x000a9; 2015, Avicenna Research Institute.</copyright-statement><copyright-year>2015</copyright-year><license><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.</license-p></license></permissions><abstract><sec><title>Background:</title><p>Polycystic ovary syndrome (PCOS) is a multifactorial, metabolic disorder. Characteristics are chronic anovulation, polycystic ovaries and hyperandrogenism. The aim of this study was to determine the effect of omega-3 supplementation on visfatin, adiponectin, and anthropometric indices in PCOS women.</p></sec><sec><title>Methods:</title><p>The study was a randomized double blind placebo-controlled clinical trial. It was conducted on 84 women with polycystic ovary syndrome (26.92&#x000b1;5.05 years, BMI=31.69 <italic>Kg/m</italic><sup>2</sup>) who referred to the fertility and infertility research center and Shahid Sadoughi hospital in Yazd. After the examination, evaluation and para-medical assessment by obstetrician, they were recruited. They took 3 capsules of omega-3 (each one contained 180 <italic>mg</italic> EPA and 120 <italic>mg</italic> DHA) or placebo (each contained 1 <italic>g</italic> paraffin) daily for 8 weeks. Statistical analysis was paired T-test and student T-test, and a p&#x0003c;0.05 was considered statistically significant.</p></sec><sec><title>Results:</title><p>After the intervention, visfatin concentration did not change in neither groups. But, at the end of the study, the mean of adiponectin concentration increased (p&#x0003c;0.001) in omega-3 group. Moreover, the mean of changes in this factor was significantly different between groups (p&#x0003c;0.005). FSH did not change in two groups of the study. However, the mean of LH decreased about 1.74 <italic>mlU/ml</italic> in omega-3 group (p&#x0003c;0.005). The mean of change of LH/FSH ratio between groups was significant (p&#x0003c;0.05). After the intervention, prolactin did not meaningfully change in both groups.</p></sec><sec><title>Conclusion:</title><p>Our results showed that 8 weeks of supplementation of omega-3 may have some beneficial effects on PCOS biochemical characteristics such as LH, LH/FSH, and adiponectin.</p></sec></abstract><kwd-group><kwd>Adiponectin</kwd><kwd>Fertility</kwd><kwd>FSH</kwd><kwd>LH</kwd><kwd>Obesity</kwd><kwd>Omega-3</kwd><kwd>PCOS</kwd><kwd>Visfatin</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Polycystic ovary syndrome (PCOS) is a multifactorial, complex genetic, endocrine and metabolic disorder. Characteristics are chronic anovulation, polycystic ovaries and hyperandrogenism (<xref rid="B1" ref-type="bibr">1</xref>). According to different criteria, 4% to 8% of women exhibit PCOS in the world (<xref rid="B2" ref-type="bibr">2</xref>). The prevalence of PCOS in Iran was 14.6% using Rott&#x02019;s definition (<xref rid="B3" ref-type="bibr">3</xref>). PCOS has a tremendous negative impact on the physiology and metabolism of the body such as metabolic syndrome, insulin resistance (IR), dyslipidemia, hypertension, hyperinsulinemia, abdominal obesity, type 2 diabetes mellitus (<xref rid="B4" ref-type="bibr">4</xref>), endometrial hyperplasia, cardiovascular disease (<xref rid="B5" ref-type="bibr">5</xref>), eating and mood disorders (<xref rid="B6" ref-type="bibr">6</xref>).</p><p>Omega-3 fatty acids are mainly found in plant oils and marine (<xref rid="B7" ref-type="bibr">7</xref>). It is beneficial for health and has protective effects on cardiovascular disease (<xref rid="B8" ref-type="bibr">8</xref>) and metabolic syndrome (<xref rid="B9" ref-type="bibr">9</xref>). In recent years, intake of omega-3 in diets is less than omega-6, and this imbalance in omega-6 to omega-3 ratio can be related to chronic diseases (<xref rid="B10" ref-type="bibr">10</xref>).</p><p>Symptoms of PCOS differ among women with PCOS and vary over time in each woman in the presence of particular precipitating factors, the most significant of which is an alteration in body weight (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>). There is evidence that obese PCOS women have more severe hyperandrogenism and a significantly higher incidence of anovulatory cycles, oligomenorrhea and/or hirsutism compared to normal weight ones (<xref rid="B12" ref-type="bibr">12</xref>) and weight has an effect on the levels of androgens (<xref rid="B13" ref-type="bibr">13</xref>), adiponectin, and visfatin (<xref rid="B14" ref-type="bibr">14</xref>). Belzung et al. demonstrated the highest dose of omega-3 causes the more reduction in fat mass (<xref rid="B16" ref-type="bibr">16</xref>). Campbell et al. showed that the impact of omega-3 on obesity is obvious (<xref rid="B17" ref-type="bibr">17</xref>).</p><p>Visfatin is an adipokine that mimics the effect of insulin and is secreted by visceral fat tissue (<xref rid="B18" ref-type="bibr">18</xref>) and it is related to insulin resistance (<xref rid="B19" ref-type="bibr">19</xref>). Visfatin is related to Body Mass Index (BMI) (<xref rid="B20" ref-type="bibr">20</xref>) and Waist to Hip Ratio (WHR) (<xref rid="B21" ref-type="bibr">21</xref>). Some studies showed that visfatin increased in subjects with abdominal obesity and PCOS (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>). Visfatin similarity to insulin may stimulate the androgen synthesis and be the pathogenesis of PCOS (<xref rid="B24" ref-type="bibr">24</xref>). The regulatory effect of omega-3 on the level of some adipokines like leptin was evaluated (<xref rid="B25" ref-type="bibr">25</xref>), but its effects on visfatin levels was limited (<xref rid="B26" ref-type="bibr">26</xref>).</p><p>Adiponectin, as another adipokine, improves insulin sensitivity and has an anti-inflammatory effect (<xref rid="B27" ref-type="bibr">27</xref>). Some studies showed a decrease in adiponectin level in PCOS women (<xref rid="B28" ref-type="bibr">28</xref>). Some studies demonstrated that the low level of adiponectin can be related to pathogenesis of PCOS and its metabolic complications (<xref rid="B29" ref-type="bibr">29</xref>). Mohammadi et al. showed the effect of omega-3 on elevating the level of adiponectin in PCOS women (<xref rid="B30" ref-type="bibr">30</xref>).</p><p>Release of LH in PCOS women is more irregular than other women (<xref rid="B31" ref-type="bibr">31</xref>). Elevation in serum LH and LH:FSH ratio in PCOS women is common (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>). Also, prolactin level is higher in these women despite FSH level (<xref rid="B34" ref-type="bibr">34</xref>). Some studies showed the effect of omega-3 on treatment of PCOS (<xref rid="B35" ref-type="bibr">35</xref>). Others showed no effect on LH and FSH after supplementation by polyunsaturated fatty acid (PUFA) (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>).</p><p>There were many studies about the effect of omega-3 on metabolic statues of many diseases (<xref rid="B38" ref-type="bibr">38</xref>&#x02013;<xref rid="B40" ref-type="bibr">40</xref>), but studies on PCOS patients were limited (<xref rid="B41" ref-type="bibr">41</xref>). Understanding the effects of omega-3 on obesity and some adipokines can be critical. The objective of this study was evaluating the effect of omega-3 supplementation on these hormone profiles, some adipokines, and some anthropometric indices in PCOS women.</p></sec><sec sec-type="methods"><title>Methods</title><p>The study was a randomized double blind placebo-controlled clinical trial and was executed from November 2011 to May 2012. It was approved by Shahid Sadoughi University of Medical Sciences&#x02019; ethics committee (IRB no 50338), Yazd, Iran. This study was a part of the large trial registered in Iranian Registry of Clinical Trial (Registry no IRCT2012071410281N1). It was conducted on 84 women with polycystic ovary syndrome (26.92&#x000b1; 5.05 years, BMI=31.69 <italic>Kg/m</italic><sup><xref rid="B2" ref-type="bibr">2</xref></sup>), referred to the fertility and infertility research center and Shahid Sadoughi hospital in Yazd. After the examination, evaluation and para-medical assessment by obstetrician, they were recruited. Inclusion criteria were: PCOS diagnostic criteria, age between 20&#x02013;40 years, and BMI of 25&#x02013;40. Exclusion criteria included metabolic disease, thyroid disease, hyperprolactinemia, hypercortisolemia, congenital adrenal hyperplasia, Cushing&#x02019;s syndrome, pituitary disorder, neoplasm, renal and liver diseases, history about intake of any drug during the last 3 months that may affect the insulin sensitivity or hormonal profile such as: oral contraceptives, glucocorticoids, ovulation induction agents, anti-diabetic and anti-obesity drugs, estrogenic, anti-androgenic or anti-hypertensive medication, being in any diet in the last 6 months, any addiction to tobacco and alcohol, taking omega-3 supplement in the last 3 months, menopause, allergy to sea foods, and the use of anti-coagulant medicine. And the participants were excluded if they needed OCP for treatment, were not willing to be in the study, did not obey the protocols of the study, or could not digest more than 20% of supplements.</p><p>The Rotterdam ESHRE/ASRM criteria for confirming the diagnosis of PCOS were: oligo-anovulation, clinical/or biochemical evidence of hyperandrogenism, and polycystic ovaries on ultrasound examination (<xref rid="B11" ref-type="bibr">11</xref>). Thorough clinical examination with special focus on clinical hyperandrogenism (<italic>i.e</italic>. hirsutism and or hypergonadism) was done.</p><p>After explaining the objectives of the study to the patients, they signed the consent form. The 24 <italic>hr</italic> recall was completed for each patient before and after the intervention to eliminate the effect of change in dietary intake. Recall&#x02019;s data were analyzed using Nutritionist 4 software (N-Squared Inc, San Bruno, CA, USA). Subjects were randomly divided in to two groups of A and B to reduce the bias. Researchers didn&#x02019;t know which groups take the omega-3 supplement or placebo until the end of the study. Both groups were given three capsules of omega-3 or placebos every day for 8 weeks (<xref rid="B42" ref-type="bibr">42</xref>). Each capsule of omega-3 contained 180 <italic>mg</italic> EPA and 120 <italic>mg</italic> DHA, and each placebo included 1 <italic>g</italic> paraffin (Zahravi, Iran). The appearance of placebo and omega-3capsules were similar. All subjects were followed weekly by phone call, and they referred to the office bimonthly to take the supplements to reduce the drop out. All participants were asked to maintain their usual diet and lifestyle habits.</p><p>For biochemical analysis, 10 <italic>ml</italic> of blood were collected from all samples before and after the intervention. Serum was kept in &#x02212;80<italic>&#x000b0;C</italic> until analysis. Serum levels of visfatin, adiponectin, LH, FSH, and prolactin were measured. The LH/FSH ratio was calculated. Serum levels of visfatin (Cusabio, China), adiponectin (Medignost, Germany), LH (DiaMetra, Germany), FSH (DiaMetra, Germany), and prolactin (DiaMetra, Germany) were measured by ELISA Reader (Statfax2600, USA).</p><p>Weight, height, and BMI (weight in <italic>kg</italic> divided by height in <italic>m</italic><sup>2</sup>) were measured before the intervention for checking the inclusion criteria.</p><p>Weight (<italic>kg</italic>) was measured twice to the nearest 0.1 <italic>kg</italic>, with no shoes. Height (<italic>m</italic>) was measured twice to the nearest 0.5 cm, with no shoes.</p><p>Statistical analysis included mean and standard deviation, percentage, ratio, chi-square, pearson correlation coefficient test, paired T-test, student T-test, ANOVA, Wilcoxon, and Mann-whitney. SPSS 12 Software was used (SPSS Inc, Chicago IL) for analyzing the data and a p-value less than 0.05 was considered statistically significant.</p></sec><sec sec-type="results"><title>Results</title><p>In this study, one of the participants became pregnant and left the study. Five participants dropped out because of taking less than 20% of our capsules. The remaining 78 participants completed the study. Finally, 78 people (92.8%) among the patients, 39 patients in the group receiving omega-3 and 39 patients in the group receiving placebo, finished the eight week trial.</p><p>Mean of age was 26.9&#x000b1;5.9 years in omega-3 and 26.9&#x000b1;5.0 years in placebo groups. Mean of BMI was 31.46&#x000b1;5.74 <italic>Kg/m</italic><sup>2</sup> in omega-3 and 31.88&#x000b1;3.86 <italic>Kg/m</italic><sup>2</sup> in placebo group. There were not any significant differences between groups in terms of age, weight, and other characters before the study.</p><p>There were no significant differences between and within groups in energy, macronutrients, omega-3, omega-6, and omega-6/mega-3 daily intake in the beginning of the study and after the intervention (<xref ref-type="table" rid="T1">Table 1</xref>).</p><table-wrap id="T1" position="float"><label>Table 1.</label><caption><p>Mean and standard deviation of intake of omega-3, omega-6, omega-6/omega-3, energy, and macronutrients between both groups before and after the intervention</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="3" colspan="1"/><th colspan="2" align="center" valign="middle" rowspan="1">
<bold>
Placebo group N=39
</bold></th><th colspan="2" align="center" valign="middle" rowspan="1">
<bold>
Supplement group N=39
</bold></th><th align="center" valign="middle" rowspan="3" colspan="1">
<bold>
P-value (between groups)
</bold></th></tr><tr><th colspan="4" align="center" valign="middle" rowspan="1">
<hr/></th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1"><bold>
SD
</bold>
&#x000b1;
<bold>
Mean
</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold>
Median
</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold>
Median
</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold>
SD
</bold>
&#x000b1;
<bold>
Mean
</bold></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>
Omega-3 (<italic>g/d</italic>)
</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Before the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">9.9&#x000b1;24.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.7</td><td align="center" valign="top" rowspan="1" colspan="1">0.8</td><td align="center" valign="top" rowspan="1" colspan="1">5.4&#x000b1;15.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.6 
<sup><xref ref-type="table-fn" rid="TFN3">***</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;After the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">14.5&#x000b1;33.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.7</td><td align="center" valign="top" rowspan="1" colspan="1">9.5&#x000b1;28.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.7 
<sup><xref ref-type="table-fn" rid="TFN3">***</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;P-value 
<sup><xref ref-type="table-fn" rid="TFN1">*</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">0.34</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.6</td><td align="center" valign="top" rowspan="1" colspan="1">--</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>
Omega-6 (<italic>g/d</italic>)
</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Before the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">32.1&#x000b1;36.9</td><td align="center" valign="top" rowspan="1" colspan="1">19.6</td><td align="center" valign="top" rowspan="1" colspan="1">19.1</td><td align="center" valign="top" rowspan="1" colspan="1">25.4&#x000b1;22.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.9 
<sup><xref ref-type="table-fn" rid="TFN3">***</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;After the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">38.1&#x000b1;52.4</td><td align="center" valign="top" rowspan="1" colspan="1">19.6</td><td align="center" valign="top" rowspan="1" colspan="1">21.4</td><td align="center" valign="top" rowspan="1" colspan="1">33.3&#x000b1;45.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.4 
<sup><xref ref-type="table-fn" rid="TFN3">***</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;P-value 
<sup><xref ref-type="table-fn" rid="TFN1">*</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">0.4</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.1</td><td align="center" valign="top" rowspan="1" colspan="1">--</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>
Omega-6/omega-3
</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Before the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">26.0&#x000b1;20.4</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">22.9&#x000b1;11.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.4 
<sup><xref ref-type="table-fn" rid="TFN4">****</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;After the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">23.4&#x000b1;20.0</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">25.1&#x000b1;12.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.6 
<sup><xref ref-type="table-fn" rid="TFN4">****</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;P-value 
<sup><xref ref-type="table-fn" rid="TFN2">**</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">0.1</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.1</td><td align="center" valign="top" rowspan="1" colspan="1">--</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>
Energy (<italic>Kcal/d</italic>)
</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Before the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">2020.2&#x000b1;262.1</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">1970&#x000b1;235.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.4 
<sup><xref ref-type="table-fn" rid="TFN4">****</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;After the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">1998.5&#x000b1;213.6</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">1960.6&#x000b1;223.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.5 
<sup><xref ref-type="table-fn" rid="TFN4">****</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;P-value 
<sup><xref ref-type="table-fn" rid="TFN2">**</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">0.3</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.6</td><td align="center" valign="top" rowspan="1" colspan="1">--</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>
Fat (<italic>g/d</italic>)
</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Before the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">78.4&#x000b1;19.1</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">79.0&#x000b1;19.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.8 
<sup><xref ref-type="table-fn" rid="TFN4">****</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;After the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">76.5&#x000b1;20.2</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">79.4&#x000b1;20.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.5 
<sup><xref ref-type="table-fn" rid="TFN4">****</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;P-value 
<sup><xref ref-type="table-fn" rid="TFN2">**</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">0.5</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.5</td><td align="center" valign="top" rowspan="1" colspan="1">--</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>
Protein (<italic>g/d</italic>)
</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Before the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">63.5&#x000b1;11.6</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">59.8&#x000b1;10.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.1 
<sup><xref ref-type="table-fn" rid="TFN4">****</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;After the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">65.1&#x000b1;12.8</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">59.6&#x000b1;9.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.3 
<sup><xref ref-type="table-fn" rid="TFN4">****</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;P-value 
<sup><xref ref-type="table-fn" rid="TFN2">**</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">0.3</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.8</td><td align="center" valign="top" rowspan="1" colspan="1">--</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>
Carbohydrate
</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Before the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">268.6&#x000b1;58.6</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">260.2&#x000b1;32.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.5 
<sup><xref ref-type="table-fn" rid="TFN4">****</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;After the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">266.5&#x000b1;41.2</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">259.2&#x000b1;29.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.3 
<sup><xref ref-type="table-fn" rid="TFN4">****</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;P-value 
<sup><xref ref-type="table-fn" rid="TFN2">**</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">0.9</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.6</td><td align="center" valign="top" rowspan="1" colspan="1">--</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>*</label><p>Wilcoxon test,</p></fn><fn id="TFN2"><label>**</label><p>Paired sample t-test,</p></fn><fn id="TFN3"><label>***</label><p>Mann-Whitney U test,</p></fn><fn id="TFN4"><label>****</label><p>Student t test</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2.</label><caption><p>Comparison of quantitative variables between both groups before and after intervention</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="4" colspan="1"/><th colspan="2" align="center" valign="middle" rowspan="1">
<bold>
Placebo group N=39
</bold></th><th colspan="2" align="center" valign="middle" rowspan="1">
<bold>
Supplement group N=39
</bold></th><th align="center" valign="middle" rowspan="4" colspan="1">
<bold>
P-value
<xref ref-type="table-fn" rid="TFN6"><sup>**</sup>
</xref></bold></th></tr><tr><th colspan="4" align="center" valign="middle" rowspan="1">
<hr/></th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1"><bold>
SD&#x000b1;Mean
</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold>
Median
</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold>
SD&#x000b1;Mean
</bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold>
Median
</bold></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>
BMI (<italic>Kg/m</italic><sup>
2
</sup>
)
</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Before the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">31.88&#x000b1;3.86</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">31.46&#x000b1;5.74</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;After the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">31.83&#x000b1;3.68</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">31.17&#x000b1;5.93</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;P-value
<sup><xref ref-type="table-fn" rid="TFN5">*</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">0.70</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.09</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">--</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Mean of change 
<sup><xref ref-type="table-fn" rid="TFN7">***</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.05&#x000b1;0.89</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.29&#x000b1;1.04</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>
WHR (<italic>cm</italic>)
</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Before the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">102.59&#x000b1;10.75</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">100.55&#x000b1;14.36</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;After the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">102.27&#x000b1;10.20</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">98.77&#x000b1;14.55</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;P-value 
<sup><xref ref-type="table-fn" rid="TFN5">*</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">0.53</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.005</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Mean of change 
<sup><xref ref-type="table-fn" rid="TFN7">***</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.32&#x000b1;3.17</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.78&#x000b1;3.21</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.28 
<sup><xref ref-type="table-fn" rid="TFN9">*****</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>
Visfatin (<italic>ng/ml</italic>)
</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Before the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">6.97&#x000b1;2.46</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">6.91&#x000b1;2.41</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.92</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;After the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">7.01&#x000b1;2.60</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">6.98&#x000b1;2.51</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.96</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;P-value 
<sup><xref ref-type="table-fn" rid="TFN5">*</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">0.61</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.34</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">--</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Mean of change 
<sup><xref ref-type="table-fn" rid="TFN7">***</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">0.04&#x000b1;0.52</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.07&#x000b1;0.44</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.82</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>
Adiponectin (<italic>ng/ml</italic>)
</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Before the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">5.16&#x000b1;3.93</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">4.44&#x000b1;1.92</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;After the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">4.65&#x000b1;3.14</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">5.62&#x000b1;2.68</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;P-value 
<sup><xref ref-type="table-fn" rid="TFN5">*</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.005</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">--</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Mean of change 
<sup><xref ref-type="table-fn" rid="TFN7">***</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.51&#x000b1;1.60</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">1.17&#x000b1;2.10</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>
FSH (<italic>mlU/ml</italic>)
</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Before the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">5.60&#x000b1;2.22</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">5.75&#x000b1;3.07</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.80</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;After the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">5.64&#x000b1;2.25</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">5.70&#x000b1;3.37</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.93</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;P-value 
<sup><xref ref-type="table-fn" rid="TFN5">*</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">0.87</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.83</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">--</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Mean of change 
<sup><xref ref-type="table-fn" rid="TFN7">***</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.04&#x000b1;1.73</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.05&#x000b1;1.50</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.79</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>
LH (<italic>mlU/ml</italic>)
</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Before the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">6.60&#x000b1;3.62</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">8.18&#x000b1;3.87</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;After the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">6.49&#x000b1;3.71</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">6.44&#x000b1;3.62</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.96</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;P-value 
<sup><xref ref-type="table-fn" rid="TFN5">*</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">0.87</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">--</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Mean of change 
<sup><xref ref-type="table-fn" rid="TFN7">***</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.11&#x000b1;4.28</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.74&#x000b1;2.76</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.050</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>
Prolactin (<italic>ng/ml</italic>)
</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Before the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">332.13&#x000b1;221.88</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">366.38&#x000b1;187.73</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.46</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;After the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">388.08&#x000b1;197.97</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">353.18&#x000b1;178.02</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.42</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;P-value 
<sup><xref ref-type="table-fn" rid="TFN5">*</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.62</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">--</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Mean of change 
<sup><xref ref-type="table-fn" rid="TFN7">***</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">55.95&#x000b1;175.16</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;13.20&#x000b1;165.14</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>
LH/FSH ratio
</bold></td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Before the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">1.38&#x000b1;1.03</td><td align="center" valign="top" rowspan="1" colspan="1">1.11</td><td align="center" valign="top" rowspan="1" colspan="1">2.09&#x000b1;3.24</td><td align="center" valign="top" rowspan="1" colspan="1">1.35</td><td align="center" valign="top" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;After the intervention</td><td align="center" valign="top" rowspan="1" colspan="1">1.33&#x000b1;0.85</td><td align="center" valign="top" rowspan="1" colspan="1">1.33</td><td align="center" valign="top" rowspan="1" colspan="1">1.33&#x000b1;0.92</td><td align="center" valign="top" rowspan="1" colspan="1">1.05</td><td align="center" valign="top" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;P-value 
<sup><xref ref-type="table-fn" rid="TFN8">****</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.98</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td><td align="center" valign="top" rowspan="1" colspan="1">--</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Mean of change 
<sup><xref ref-type="table-fn" rid="TFN7">***</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.05&#x000b1;1.13</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.76&#x000b1;2.94</td><td align="center" valign="top" rowspan="1" colspan="1">--</td><td align="center" valign="top" rowspan="1" colspan="1">0.02 
<sup><xref ref-type="table-fn" rid="TFN9">*****</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="TFN5"><label>*</label><p>Paired sample t-test,</p></fn><fn id="TFN6"><label>**</label><p>Independent sample t-test,</p></fn><fn id="TFN7"><label>***</label><p>Data after the study- first data,</p></fn><fn id="TFN8"><label>****</label><p>Wilcoxon test,</p></fn><fn id="TFN9"><label>*****</label><p>Mann-Whitney U test</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>The results of our study showed that omega-3 treatment was associated with significant improvement with LH, adiponectin concentration, WHR, and LH/FSH ratio in PCOS.</p><p>According to this study, no changes were seen in energy and macronutrient intakes and BMI in both groups after the intervention. These findings were similar to previous studies (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B43" ref-type="bibr">43</xref>). The study of Mohammadi et al. showed no changes in WHR after 8 weeks of supplementation (<xref rid="B30" ref-type="bibr">30</xref>). However, some studies showed a reduction in WHR, BMI after 8 weeks of omega-3 supplementation in women with type 2 diabetes (<xref rid="B26" ref-type="bibr">26</xref>) and reduction of weight in mice (<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B45" ref-type="bibr">45</xref>). Obesity and its comorbidities (diabetes, cancer, and heart disease) are linked to inflammation. Omega-3 had anti-inflammatory properties and has some effects on mediating receptors (<xref rid="B46" ref-type="bibr">46</xref>).</p><p>Our result about adiponectin level was compatible to previous studies in human (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B48" ref-type="bibr">48</xref>) and animals (<xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B50" ref-type="bibr">50</xref>). The stimulation of Adipoq (adiponectin gene) in adipose tissue as a ligand of PPAR-&#x003b3; (peroxisome proliferator-activated receptor &#x003b3;) is one of the effects of EPA and DHA (<xref rid="B44" ref-type="bibr">44</xref>).</p><p>Evidence about the effect of omega-3 on visfatin level is limited. According to the study of Hajianfar et al., visfatin concentration increased after 8 weeks of the omega-3 supplementation (2 capsule/day, each capsule contain EPA 360 mg, DHA 240 <italic>mg</italic>) (<xref rid="B26" ref-type="bibr">26</xref>). In an <italic>in vitro</italic> study, it was suggested that AMPK activation has a role in upregulation of visfatin gene after omega-3 intervention (<xref rid="B51" ref-type="bibr">51</xref>). This study showed no effect of omega-3 on visfatin level. The duration of the study and dose of EPA/DHA may not be enough to detect visfatin changes.</p><p>The improvement of LH concentration and LH/FSH ratio can cause the improvement of reproductive system. This trend can be explained by the mechanism related to arachidonic acids (<xref rid="B52" ref-type="bibr">52</xref>). Arachidonic acid can activate a steroidogenic acute regulatory protein (StAR). StAR is the rate-limiting step in steroidogenic pathway. High arachidonic acid can make 2-series prostaglandins (PGs), thromboxanes (TXs), and 4-series leukoterienes (LTs) and they induce StAR. However, high aracchidonic acid can activate the LH-stimulated steroidogenesis. Increase of omega-3 in membrane can reduce the availability of arachidonic acid. So, StAR moves the cholesterol to the inner of mitochondrial membrane. It is the first and main step for steriodogenic pathway which results in production of androstenedione and testosterone (<xref rid="B52" ref-type="bibr">52</xref>).</p><p>Our data showed that omega-3 supplementation in 8 weeks has no effect on FSH concentration in PCOS women. These results are similar to the results of Kuzmanov et al.&#x02019;s study. They examined 3 months of n-3 PUFA application on hormone status in 12 PCOS samples, but they did not see any changes on FSH concentration (<xref rid="B53" ref-type="bibr">53</xref>). Karakas et al.&#x02019;s study showed similar results (<xref rid="B36" ref-type="bibr">36</xref>).</p><p>In our study, LH concentration and LH/FSH ratio significantly decreased after the intervention. Some studies showed no changes in LH concentration (<xref rid="B52" ref-type="bibr">52</xref>) and LH/FSH ratio after the intervention (<xref rid="B37" ref-type="bibr">37</xref>) like Karakas et al.&#x02019;s study in using rich-PUFA diet for 3 months (<xref rid="B36" ref-type="bibr">36</xref>). Karakas suggested the intervention with more participants.</p><p>The concentration of prolactin after this study did not meaningfully change. No similar study about variation of prolactin in this case was found.</p><p>The strength of the current study was the clinical trial design. The limitation of our study was a shortness of intervention period and the clinical impacts were not collected. It is suggested that more clinical trials be conducted in this field with longer duration of intervention and in women with similar pattern of ovulations.</p><p>It has been suggested to design other studies with longer intervention. So, the effect of omega-3 could be more obvious. It has been suggested to measure the concentration of fatty acid on RBC membrane to check the protocol adherence and effect of omega-3 on other adipokines.</p></sec><sec sec-type="conclusion"><title>Conclusion</title><p>Omega-3 supplementation in PCOS women can show a benefit effect on adiponectin, LH concentration, WHR, and LH/FSH ratio. This effect was not associated with BMI, visfatin, FSH, and prolactin levels.</p></sec></body><back><ack><title>Acknowledgement</title><p>This study was derived from a master&#x02019;s dissertation. We thank the Research &#x00026; Clinical Center of Infertility in Yazd for their support. We are extremely grateful to Maryam Chamari for her wise collaboration in this study.</p></ack><fn-group><fn><p><bold>Conflict of Interest</bold></p><p>The authors declare that they have no conflict of interests.</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Witchel</surname><given-names>SF</given-names></name></person-group>
<article-title>Puberty and polycystic ovary syndrome</article-title>. 
<source>Mol Cell Endocrinol</source>. 
<year>2006</year>;
<fpage>254</fpage>&#x02013;
<lpage>255</lpage>:
<fpage>146</fpage>&#x02013;
<lpage>53</lpage>.
</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moran</surname><given-names>LJ</given-names></name><name><surname>Hutchison</surname><given-names>SK</given-names></name><name><surname>Norman</surname><given-names>RJ</given-names></name><name><surname>Teede</surname><given-names>HJ</given-names></name></person-group>
<article-title>Lifestyle changes in women with polycystic ovary syndrome</article-title>. 
<source>Cochrane Database Syst Rev</source>. 
<year>2011</year>;
(<issue>7</issue>): 
<fpage>CD007506</fpage>.
</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tehrani</surname><given-names>FR</given-names></name><name><surname>Simbar</surname><given-names>M</given-names></name><name><surname>Tohidi</surname><given-names>M</given-names></name><name><surname>Hosseinpanah</surname><given-names>F</given-names></name><name><surname>Azizi</surname><given-names>F</given-names></name></person-group>
<article-title>The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study</article-title>. 
<source>Reprod Biol Endocrinol</source>. 
<year>2011</year>;
<volume>9</volume>:
<fpage>39</fpage>.
<pub-id pub-id-type="pmid">21435276</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Franks</surname><given-names>S</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>Hardy</surname><given-names>K</given-names></name></person-group>
<article-title>Development of polycystic ovary syndrome: involvement of genetic and environmental factors</article-title>. 
<source>Int J Androl</source>. 
<year>2006</year>;
<volume>29</volume>
(<issue>1</issue>): 
<fpage>278</fpage>&#x02013;
<lpage>85</lpage>.
<pub-id pub-id-type="pmid">16390494</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xita</surname><given-names>N</given-names></name><name><surname>Georgiou</surname><given-names>I</given-names></name><name><surname>Tsatsoulis</surname><given-names>A</given-names></name></person-group>
<article-title>The genetic basis of polycystic ovary syndrome</article-title>. 
<source>Eur J Endocrinol</source>. 
<year>2002</year>;
<volume>147</volume>
(<issue>6</issue>):
<fpage>717</fpage>&#x02013;
<lpage>25</lpage>.
<pub-id pub-id-type="pmid">12457445</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goodarzi</surname><given-names>MO</given-names></name><name><surname>Dumesic</surname><given-names>DA</given-names></name><name><surname>Chazenbalk</surname><given-names>G</given-names></name><name><surname>Azziz</surname><given-names>R</given-names></name></person-group>
<article-title>Polycystic ovary syndrome: etiology, pathogenesis and diagnosis</article-title>. 
<source>Nat Rev Endocrinol</source>. 
<year>2011</year>;
<volume>7</volume>
(<issue>4</issue>): 
<fpage>219</fpage>&#x02013;
<lpage>31</lpage>.
<pub-id pub-id-type="pmid">21263450</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kwintkiewicz</surname><given-names>J</given-names></name><name><surname>Spaczynski</surname><given-names>RZ</given-names></name><name><surname>Foyouzi</surname><given-names>N</given-names></name><name><surname>Pehlivan</surname><given-names>T</given-names></name><name><surname>Duleba</surname><given-names>AJ</given-names></name></person-group>
<article-title>Insulin and oxidative stress modulate proliferation of rat ovarian theca-interstitial cells through diverse signal transduction pathways</article-title>. 
<source>Biol Reprod</source>. 
<year>2006</year>;
<volume>74</volume>
(<issue>6</issue>):
<fpage>1034</fpage>&#x02013;
<lpage>40</lpage>.
<pub-id pub-id-type="pmid">16481589</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name></person-group>
<article-title>Effects of dietary fish oil and trans fat on rat aorta histopathology and cardiovascular risk markers</article-title>. 
<source>Nutr Res Pract</source>. 
<year>2009</year>;
<volume>3</volume>
(<issue>2</issue>):
<fpage>102</fpage>&#x02013;
<lpage>7</lpage>.
<pub-id pub-id-type="pmid">20016709</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Poudyal</surname><given-names>H</given-names></name><name><surname>Panchal</surname><given-names>SK</given-names></name><name><surname>Diwan</surname><given-names>V</given-names></name><name><surname>Brown</surname><given-names>L</given-names></name></person-group>
<article-title>Omega-3 fatty acids and metabolic syndrome: effects and emerging mechanisms of action</article-title>. 
<source>Prog Lipid Res</source>. 
<year>2011</year>;
<volume>50</volume>
(<issue>4</issue>):
<fpage>372</fpage>&#x02013;
<lpage>87</lpage>.
<pub-id pub-id-type="pmid">21762726</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>ML</given-names></name></person-group>
<source>Krause&#x02019;s food and nutrition therapy</source>. 
<edition>12th ed</edition>
<publisher-loc>St Louis, Missouri</publisher-loc>: 
<publisher-name>Saunders Elsevier</publisher-name>; 
<year>2008</year> Chapter 3, The nutrients and their metabolism; p. 
<fpage>39</fpage>&#x02013;
<lpage>143</lpage>.
</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Allahbadia</surname><given-names>GN</given-names></name><name><surname>Merchant</surname><given-names>R</given-names></name></person-group>
<article-title>Polycystic ovary syndrome and impact on health</article-title>. 
<source>Middle East Fertil Soc J</source>. 
<year>2010</year>;
<volume>16</volume>
(<issue>1</issue>):
<fpage>19</fpage>&#x02013;
<lpage>37</lpage>.
</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xita</surname><given-names>N</given-names></name><name><surname>Tsatsoulis</surname><given-names>A</given-names></name></person-group>
<article-title>Review: Fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies</article-title>. 
<source>J Clin Endocrinol Metab</source>. 
<year>2006</year>; 
<volume>91</volume>
(<issue>5</issue>):
<fpage>1660</fpage>&#x02013;
<lpage>6</lpage>.
<pub-id pub-id-type="pmid">16522691</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Piouka</surname><given-names>A</given-names></name><name><surname>Farmakiotis</surname><given-names>D</given-names></name><name><surname>Katsikis</surname><given-names>I</given-names></name><name><surname>Macut</surname><given-names>D</given-names></name><name><surname>Gerou</surname><given-names>S</given-names></name><name><surname>Panidis</surname><given-names>D</given-names></name></person-group>
<article-title>Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels</article-title>. 
<source>Am J Physiol Endocrinol Metab</source>. 
<year>2009</year>;
<volume>296</volume>
(<issue>2</issue>):
<fpage>E238</fpage>&#x02013;
<lpage>43</lpage>.
<pub-id pub-id-type="pmid">18957615</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fantuzzi</surname><given-names>G</given-names></name></person-group>
<article-title>Adipose tissue, adipokines, and inflammation</article-title>. 
<source>J Allergy Clin Immunol</source>. 
<year>2005</year>;
<volume>115</volume>
(<issue>5</issue>): 
<fpage>911</fpage>&#x02013;
<lpage>9</lpage>.
<pub-id pub-id-type="pmid">15867843</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hainault</surname><given-names>I</given-names></name><name><surname>Carlotti</surname><given-names>M</given-names></name><name><surname>Hajduch</surname><given-names>E</given-names></name><name><surname>Guichard</surname><given-names>C</given-names></name><name><surname>Lavau</surname><given-names>M</given-names></name></person-group>
<article-title>Fish oil in a high lard diet prevents obesity, hyperlipemia, and adipocyte insulin resistance in rats</article-title>. 
<source>Ann N Y Acad Sci</source>. 
<year>1993</year>;
<volume>683</volume>:
<fpage>98</fpage>&#x02013;
<lpage>101</lpage>.
<pub-id pub-id-type="pmid">8352478</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Belzung</surname><given-names>F</given-names></name><name><surname>Raclot</surname><given-names>T</given-names></name><name><surname>Groscolas</surname><given-names>R</given-names></name></person-group>
<article-title>Fish oil n-3 fatty acids selectively limit the hypertrophy of abdominal fat depots in growing rats fed high-fat diets</article-title>. 
<source>Am J Physiol</source>. 
<year>1993</year>;
<volume>264</volume>
(<issue>6 Pt 2</issue>):
<fpage>R1111</fpage>&#x02013;
<lpage>8</lpage>.
<pub-id pub-id-type="pmid">8322963</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sara</surname><given-names>CC</given-names></name><name><surname>Bello</surname><given-names>NT</given-names></name></person-group>
<article-title>Omega-3 Fatty Acids and Obesity</article-title>. 
<source>J Food Nutr Disord</source>. 
<year>2012</year>;
<volume>1</volume>:
<fpage>2</fpage>.
</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stofkova</surname><given-names>A</given-names></name></person-group>
<article-title>Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity</article-title>. 
<source>Endocr Regul</source>. 
<year>2010</year>;
<volume>44</volume>
(<issue>1</issue>):
<fpage>25</fpage>&#x02013;
<lpage>36</lpage>.
<pub-id pub-id-type="pmid">20151765</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Plati</surname><given-names>E</given-names></name><name><surname>Kouskouni</surname><given-names>E</given-names></name><name><surname>Malamitsi-Puchner</surname><given-names>A</given-names></name><name><surname>Boutsikou</surname><given-names>M</given-names></name><name><surname>Kaparos</surname><given-names>G</given-names></name><name><surname>Baka</surname><given-names>S</given-names></name></person-group>
<article-title>Visfatin and leptin levels in women with polycystic ovaries undergoing ovarian stimulation</article-title>. 
<source>Fertil Steril</source>. 
<year>2010</year>;
<volume>94</volume>
(<issue>4</issue>): 
<fpage>1451</fpage>&#x02013;
<lpage>6</lpage>.
<pub-id pub-id-type="pmid">19523615</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Varma</surname><given-names>V</given-names></name><name><surname>Yao-Borengasse</surname><given-names>A</given-names></name><name><surname>Rasouli</surname><given-names>N</given-names></name><name><surname>Bodles</surname><given-names>AM</given-names></name><name><surname>Phanavanh</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>MJ</given-names></name><etal/></person-group>
<article-title>Human visfatin expression: relationship to insulin sensitivity, intra-myocellular lipids, and inflammation</article-title>. 
<source>J Clin Endocrinol Metab</source>. 
<year>2007</year>;
<volume>92</volume>
(<issue>2</issue>):
<fpage>666</fpage>&#x02013;
<lpage>72</lpage>.
<pub-id pub-id-type="pmid">17090638</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>MP</given-names></name><name><surname>Chung</surname><given-names>FM</given-names></name><name><surname>Chang</surname><given-names>DM</given-names></name><name><surname>Tsai</surname><given-names>JC</given-names></name><name><surname>Huang</surname><given-names>HF</given-names></name><name><surname>Shin</surname><given-names>SJ</given-names></name><etal/></person-group>
<article-title>Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus</article-title>. 
<source>J Clin Endocrinol Metab</source>. 
<year>2006</year>;
<volume>91</volume>
(<issue>1</issue>):
<fpage>295</fpage>&#x02013;
<lpage>9</lpage>.
<pub-id pub-id-type="pmid">16234302</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ozkaya</surname><given-names>M</given-names></name><name><surname>Cakal</surname><given-names>E</given-names></name><name><surname>Ustun</surname><given-names>Y</given-names></name><name><surname>Engin-Ustun</surname><given-names>Y</given-names></name></person-group>
<article-title>Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome</article-title>. 
<source>Fertil Steril</source>. 
<year>2010</year>;
<volume>93</volume>
(<issue>3</issue>):
<fpage>880</fpage>&#x02013;
<lpage>4</lpage>.
<pub-id pub-id-type="pmid">19111298</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sandeep</surname><given-names>S</given-names></name><name><surname>Velmurugan</surname><given-names>K</given-names></name><name><surname>Deepa</surname><given-names>R</given-names></name><name><surname>Mohan</surname><given-names>V</given-names></name></person-group>
<article-title>Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians</article-title>. 
<source>Metabolism</source>. 
<year>2007</year>;
<volume>56</volume>
(<issue>4</issue>):
<fpage>565</fpage>&#x02013;
<lpage>70</lpage>.
<pub-id pub-id-type="pmid">17379018</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kowalska</surname><given-names>I</given-names></name><name><surname>Straczkowski</surname><given-names>M</given-names></name><name><surname>Nikolajuk</surname><given-names>A</given-names></name><name><surname>Adamska</surname><given-names>A</given-names></name><name><surname>Karczewska-Kupczewska</surname><given-names>M</given-names></name><name><surname>Otziomek</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome</article-title>. 
<source>Hum Reprod</source>. 
<year>2007</year>;
<volume>22</volume>
(<issue>7</issue>):
<fpage>1824</fpage>&#x02013;
<lpage>9</lpage>.
<pub-id pub-id-type="pmid">17582143</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rossi</surname><given-names>AS</given-names></name><name><surname>Lombardo</surname><given-names>YB</given-names></name><name><surname>Lacorte</surname><given-names>JM</given-names></name><name><surname>Chicco</surname><given-names>AG</given-names></name><name><surname>Rouault</surname><given-names>Ch</given-names></name><name><surname>Slama</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Dietary fish oil positively regulates plasma leptin and adiponectin levels in sucrose-fed, insulin-resistant rats</article-title>. 
<source>Am J Physiol Regul Integr Comp Physiol</source>. 
<year>2005</year>;
<volume>289</volume>
(<issue>2</issue>): 
<fpage>R486</fpage>&#x02013;
<lpage>R494</lpage>.
<pub-id pub-id-type="pmid">16014450</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hajianfar</surname><given-names>H</given-names></name><name><surname>Hosseinzadeh</surname><given-names>MJ</given-names></name><name><surname>Bahonar</surname><given-names>A</given-names></name><name><surname>Mohammad</surname><given-names>K</given-names></name><name><surname>Askari</surname><given-names>GR</given-names></name><name><surname>Entezari</surname><given-names>MH</given-names></name><etal/></person-group>
<article-title>The effect of omega-3 on the serum visfatin concentration in patients with type II diabetes</article-title>. 
<source>J Res Med Sci</source>. 
<year>2011</year>;
<volume>16</volume>
(<issue>4</issue>):
<fpage>490</fpage>&#x02013;
<lpage>5</lpage>.
<pub-id pub-id-type="pmid">22091264</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mamaghani</surname><given-names>F</given-names></name><name><surname>Zarghami</surname><given-names>N</given-names></name><name><surname>Malekiet</surname><given-names>MJ</given-names></name><name><surname>Pourhassan-Moghaddam</surname><given-names>M</given-names></name><name><surname>Hosseinpanah</surname><given-names>F</given-names></name></person-group>
<article-title>Variation of adiponectin levels in normal and obese subjects: possible correlation with lipid profiles</article-title>. 
<source>Int J Endocrinol Metab</source>. 
<year>2009</year>;
<volume>7</volume>
(<issue>3</issue>):
<fpage>170</fpage>&#x02013;
<lpage>8</lpage>.
</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Panidis</surname><given-names>D</given-names></name><name><surname>Kourtis</surname><given-names>A</given-names></name><name><surname>Farmakiotis</surname><given-names>D</given-names></name><name><surname>Mouslech</surname><given-names>T</given-names></name><name><surname>Rousso</surname><given-names>D</given-names></name><name><surname>Koliakos</surname><given-names>G</given-names></name></person-group>
<article-title>Serum adiponectin levels in women with polycystic ovary syndrome</article-title>. 
<source>Hum Reprod</source>. 
<year>2003</year>;
<volume>18</volume>
(<issue>9</issue>):
<fpage>1790</fpage>&#x02013;
<lpage>6</lpage>.
<pub-id pub-id-type="pmid">12923129</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Escobar-Morreale</surname><given-names>HF</given-names></name><name><surname>Villuendas</surname><given-names>G</given-names></name><name><surname>Botella-Carretero</surname><given-names>JI</given-names></name><name><surname>Alvarez-Blasco</surname><given-names>F</given-names></name><name><surname>Sanchon</surname><given-names>R</given-names></name><name><surname>Luque-Ramirez</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study</article-title>. 
<source>Hum Reprod</source>. 
<year>2006</year>;
<volume>21</volume>
(<issue>9</issue>):
<fpage>2257</fpage>&#x02013;
<lpage>65</lpage>.
<pub-id pub-id-type="pmid">16675483</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mohammadi</surname><given-names>E</given-names></name><name><surname>Rafraf</surname><given-names>M</given-names></name><name><surname>Farzadi</surname><given-names>L</given-names></name><name><surname>Asghari-Jafarabadi</surname><given-names>M</given-names></name><name><surname>Sabour</surname><given-names>S</given-names></name></person-group>
<article-title>Effects of omega-3 fatty acids supplementation on serum adiponectin levels and some metabolic risk factors in women with polycystic ovary syndrome</article-title>. 
<source>Asia Pac J Clin Nutr</source>. 
<year>2012</year>;
<volume>21</volume>
(<issue>4</issue>):
<fpage>511</fpage>&#x02013;
<lpage>8</lpage>.
<pub-id pub-id-type="pmid">23017309</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barontini</surname><given-names>M</given-names></name><name><surname>Garcia-Rudaz</surname><given-names>MC</given-names></name><name><surname>Veldhuis</surname><given-names>JD</given-names></name></person-group>
<article-title>Mechanisms of hypothalamic-pituitary-gonadal disruption in polycystic ovarian syndrome</article-title>. 
<source>Arch Med Res</source>. 
<year>2001</year>;
<volume>32</volume>
(<issue>6</issue>):
<fpage>544</fpage>&#x02013;
<lpage>52</lpage>.
<pub-id pub-id-type="pmid">11750729</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spritzer</surname><given-names>PM</given-names></name><name><surname>Poy</surname><given-names>M</given-names></name><name><surname>Wiltgen</surname><given-names>D</given-names></name><name><surname>Mylius</surname><given-names>LS</given-names></name><name><surname>Capp</surname><given-names>E</given-names></name></person-group>
<article-title>Leptin concentrations in hirsute women with polycystic ovary syndrome or idiopathic hirsutism: influence on LH and relationship with hormonal, metabolic, and anthropometric measurements</article-title>. 
<source>Hum Reprod</source>. 
<year>2001</year>;
<volume>16</volume>
(<issue>7</issue>):
<fpage>1340</fpage>&#x02013;
<lpage>6</lpage>.
<pub-id pub-id-type="pmid">11425810</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Banaszewska</surname><given-names>B</given-names></name><name><surname>Spaczynski</surname><given-names>RZ</given-names></name><name><surname>Pelesz</surname><given-names>M</given-names></name><name><surname>Pawelczyk</surname><given-names>L</given-names></name></person-group>
<article-title>Incidence of elevated LH/FSH ratio in polycystic ovary syndrome women with normo- and hyperinsulinemia</article-title>. 
<source>Rocz Akad Med Bialymst</source>. 
<year>2003</year>; 
<volume>48</volume>:
<fpage>131</fpage>&#x02013;
<lpage>4</lpage>.
<pub-id pub-id-type="pmid">14737959</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>P</given-names></name></person-group>
<article-title>[Clinical significance and changes of serum visfatin, adiponectin and leptin levels in patients with polycystic ovarian syndrome]</article-title>. 
<source>Zhong Nan Da Xue Xue Bao Yi Xue Ban</source>. 
<year>2009</year>;
<volume>34</volume>
(<issue>1</issue>):
<fpage>72</fpage>&#x02013;
<lpage>5</lpage>. Chinese.
<pub-id pub-id-type="pmid">19197132</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lydic</surname><given-names>M</given-names></name><name><surname>Juturu</surname><given-names>V</given-names></name></person-group>
<article-title>Dietary approaches and alternative therapies for polycystic ovary syndrome</article-title>. 
<source>Curr Nutr Food Sci</source>. 
<year>2008</year>;
<volume>4</volume>
(<issue>4</issue>):
<fpage>265</fpage>&#x02013;
<lpage>81</lpage>.
</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kasim-Karakas</surname><given-names>SE</given-names></name><name><surname>Almario</surname><given-names>RU</given-names></name><name><surname>Gregory</surname><given-names>L</given-names></name><name><surname>Wong</surname><given-names>R</given-names></name><name><surname>Todd</surname><given-names>H</given-names></name><name><surname>Lasley</surname><given-names>BL</given-names></name></person-group>
<article-title>Metabolic and endocrine effects of a polyunsaturated fatty acid-rich diet in polycystic ovary syndrome</article-title>. 
<source>J Clin Endocrinol Metab</source>. 
<year>2004</year>;
<volume>89</volume>
(<issue>2</issue>):
<fpage>615</fpage>&#x02013;
<lpage>20</lpage>.
<pub-id pub-id-type="pmid">14764771</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="thesis">
<person-group person-group-type="author"><name><surname>Kuzmanov</surname><given-names>AP</given-names></name></person-group>
<source>Do omega-3 fatty acids affect hormones related to polycystic ovary syndrome infertility?</source> [master&#x02019;s thesis]. [United States]: University of Wyoming; 
<year>2010</year>
<fpage>81</fpage> p.
</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ebbesson</surname><given-names>SO</given-names></name><name><surname>Risica</surname><given-names>PM</given-names></name><name><surname>Ebbesson</surname><given-names>LO</given-names></name><name><surname>Kennish</surname><given-names>JM</given-names></name><name><surname>Tejero</surname><given-names>ME</given-names></name></person-group>
<article-title>Omega-3 fatty acids improve glucose tolerance and components of the metabolic syndrome in Alaskan Eskimos: the Alaska Siberia project</article-title>. 
<source>Int J Circumpolar Health</source>. 
<year>2005</year>;
<volume>64</volume>
(<issue>4</issue>):
<fpage>396</fpage>&#x02013;
<lpage>408</lpage>.
<pub-id pub-id-type="pmid">16277123</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harris</surname><given-names>WS</given-names></name><name><surname>Miller</surname><given-names>M</given-names></name><name><surname>Tighe</surname><given-names>AP</given-names></name><name><surname>Davidson</surname><given-names>MH</given-names></name><name><surname>Schaefer</surname><given-names>EJ</given-names></name></person-group>
<article-title>Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives</article-title>. 
<source>Atherosclerosis</source>. 
<year>2008</year>;
<volume>197</volume>
(<issue>1</issue>):
<fpage>12</fpage>&#x02013;
<lpage>24</lpage>.
<pub-id pub-id-type="pmid">18160071</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anil</surname><given-names>E</given-names></name></person-group>
<article-title>The impact of EPA and DHA on blood lipids and lipoprotein metabolism: influence of apoE genotype</article-title>. 
<source>Proc Nutr Soc</source>. 
<year>2007</year>;
<volume>66</volume>
(<issue>1</issue>):
<fpage>60</fpage>&#x02013;
<lpage>8</lpage>.
<pub-id pub-id-type="pmid">17343773</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cussons</surname><given-names>AJ</given-names></name><name><surname>Watts</surname><given-names>GF</given-names></name><name><surname>Mori</surname><given-names>TA</given-names></name><name><surname>Stuckey</surname><given-names>BG</given-names></name></person-group>
<article-title>Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy</article-title>. 
<source>J Clin Endocrinol Metab</source>. 
<year>2009</year>;
<volume>94</volume>
(<issue>10</issue>):
<fpage>3842</fpage>&#x02013;
<lpage>8</lpage>.
<pub-id pub-id-type="pmid">19622617</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rafraf</surname><given-names>M</given-names></name><name><surname>Mohammadi</surname><given-names>E</given-names></name><name><surname>Asghari-Jafarabadi</surname><given-names>M</given-names></name><name><surname>Farzadi</surname><given-names>L</given-names></name></person-group>
<article-title>Omega-3 fatty acids improve glucose metabolism without effects on obesity values and serum visfatin levels in women with polycystic ovary syndrome</article-title>. 
<source>J Am Coll Nutr</source>. 
<year>2012</year>;
<volume>31</volume>
(<issue>5</issue>):
<fpage>361</fpage>&#x02013;
<lpage>8</lpage>.
<pub-id pub-id-type="pmid">23529993</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vargas</surname><given-names>ML</given-names></name><name><surname>Almario</surname><given-names>RU</given-names></name><name><surname>Buchan</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Karakas</surname><given-names>SE</given-names></name></person-group>
<article-title>Metabolic and endocrine effects of long-chain versus essential omega-3 polyunsaturated fatty acids in polycystic ovary syndrome</article-title>. 
<source>Metabolism</source>. 
<year>2011</year>;
<volume>60</volume>
(<issue>12</issue>):
<fpage>1711</fpage>&#x02013;
<lpage>8</lpage>.
<pub-id pub-id-type="pmid">21640360</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Flachs</surname><given-names>P</given-names></name><name><surname>Mohamed-Ali</surname><given-names>V</given-names></name><name><surname>Horakova</surname><given-names>O</given-names></name><name><surname>Rossmeisl</surname><given-names>M</given-names></name><name><surname>Hosseinzadeh-Attar</surname><given-names>MJ</given-names></name><name><surname>Hensler</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet</article-title>. 
<source>Diabetologia</source>. 
<year>2006</year>;
<volume>49</volume>
(<issue>2</issue>):
<fpage>394</fpage>&#x02013;
<lpage>7</lpage>.
<pub-id pub-id-type="pmid">16397791</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakatani</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Kaburagi</surname><given-names>Y</given-names></name><name><surname>Yasuda</surname><given-names>K</given-names></name><name><surname>Ezaki</surname><given-names>O</given-names></name></person-group>
<article-title>A low fish oil inhibits SREBP-1 proteolytic cascade, while a high-fish-oil feeding decreases SREBP-1 mRNA in mice liver: relationship to anti-obesity</article-title>. 
<source>J Lipid Res</source>. 
<year>2003</year>;
<volume>44</volume>
(<issue>2</issue>):
<fpage>369</fpage>&#x02013;
<lpage>79</lpage>.
<pub-id pub-id-type="pmid">12576519</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oh</surname><given-names>DY</given-names></name><name><surname>Talukdar</surname><given-names>S</given-names></name><name><surname>Bae</surname><given-names>EJ</given-names></name><name><surname>Imamura</surname><given-names>T</given-names></name><name><surname>Morinaga</surname><given-names>H</given-names></name><name><surname>Fan</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects</article-title>. 
<source>Cell</source>. 
<year>2010</year>;
<volume>142</volume>
(<issue>5</issue>):
<fpage>687</fpage>&#x02013;
<lpage>98</lpage>.
<pub-id pub-id-type="pmid">20813258</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kondo</surname><given-names>K</given-names></name><name><surname>Morino</surname><given-names>K</given-names></name><name><surname>Nishio</surname><given-names>Y</given-names></name><name><surname>Kondo</surname><given-names>M</given-names></name><name><surname>Fuke</surname><given-names>T</given-names></name><name><surname>Ugi</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Effects of a fish-based diet on the serum adiponectin concentration in young, non-obese, healthy Japanese subjects</article-title>. 
<source>J Atheroscler Thromb</source>. 
<year>2010</year>;
<volume>17</volume>
(<issue>6</issue>):
<fpage>628</fpage>&#x02013;
<lpage>37</lpage>.
<pub-id pub-id-type="pmid">20299737</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Itoh</surname><given-names>M</given-names></name><name><surname>Suganami</surname><given-names>T</given-names></name><name><surname>Satoh</surname><given-names>N</given-names></name><name><surname>Tanimoto-Koyama</surname><given-names>K</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects</article-title>. 
<source>Arterioscler Thromb Vasc Biol</source>. 
<year>2007</year>;
<volume>27</volume>
(<issue>9</issue>): 
<fpage>1918</fpage>&#x02013;
<lpage>25</lpage>.
<pub-id pub-id-type="pmid">17569885</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Duda</surname><given-names>MK</given-names></name><name><surname>O&#x02019;Shea</surname><given-names>KM</given-names></name><name><surname>Lei</surname><given-names>B</given-names></name><name><surname>Barrows</surname><given-names>BR</given-names></name><name><surname>Azimzadeh</surname><given-names>AM</given-names></name><name><surname>McElfresh</surname><given-names>TE</given-names></name><etal/></person-group>
<article-title>Dietary supplementation with omega-3 PUFA increases adiponectin and attenuates ventricular remodeling and dysfunction with pressure overload</article-title>. 
<source>Cardiovasc Res</source>. 
<year>2007</year>;
<volume>76</volume>
(<issue>2</issue>):
<fpage>303</fpage>&#x02013;
<lpage>10</lpage>.
<pub-id pub-id-type="pmid">17643403</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Higuchi</surname><given-names>T</given-names></name><name><surname>Shirai</surname><given-names>N</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Kagawa</surname><given-names>Y</given-names></name></person-group>
<article-title>Levels of plasma insulin, leptin and adiponectin, and activities of key enzymes in carbohydrate metabolism in skeletal muscle and liver in fasted ICR mice fed dietary n-3 polyunsaturated fatty acids</article-title>. 
<source>J Nutr Biochem</source>. 
<year>2008</year>;
<volume>19</volume>
(<issue>9</issue>):
<fpage>577</fpage>&#x02013;
<lpage>86</lpage>.
<pub-id pub-id-type="pmid">17911005</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nettleton</surname><given-names>JA</given-names></name><name><surname>Katz</surname><given-names>R</given-names></name></person-group>
<article-title>n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review</article-title>. 
<source>J Am Diet Assoc</source>. 
<year>2005</year>;
<volume>105</volume>
(<issue>3</issue>):
<fpage>428</fpage>&#x02013;
<lpage>40</lpage>.
<pub-id pub-id-type="pmid">15746832</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Phelan</surname><given-names>N</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>A</given-names></name><name><surname>Kyaw Tun</surname><given-names>T</given-names></name><name><surname>Correia</surname><given-names>N</given-names></name><name><surname>Boran</surname><given-names>G</given-names></name><name><surname>Roche</surname><given-names>HM</given-names></name><etal/></person-group>
<article-title>Hormonal and metabolic effects of polyunsaturated fatty acids in young women with polycystic ovary syndrome: results from a cross-sectional analysis and a randomized, placebo-controlled, crossover trial</article-title>. 
<source>Am J Clin Nutr</source>. 
<year>2011</year>;
<volume>93</volume>
(<issue>3</issue>):
<fpage>652</fpage>&#x02013;
<lpage>62</lpage>.
<pub-id pub-id-type="pmid">21270384</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="confproc">
<person-group person-group-type="author"><name><surname>Kuzmanov</surname><given-names>A</given-names></name><name><surname>Broughton</surname><given-names>KS</given-names></name></person-group>
<article-title>Role of marine omega-3 fatty acids in PCOS cancer risk</article-title>. 
<conf-name>Proceedings of the 13th World Congress on Controversies in Obstetrics, Gynecology &#x00026; Infertility (COGI)</conf-name>; 
<conf-date>2010 November 4&#x02013;7</conf-date>; 
<conf-loc>Berlin, Germany</conf-loc>: 
<publisher-name>Monduzzi Editore</publisher-name>; 
<fpage>c2010</fpage> p. 
<fpage>349</fpage>&#x02013;
<lpage>351</lpage>.
</mixed-citation></ref></ref-list></back></article>